BioSpace News Archive

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and Biogen Inc. (Nasdaq: BIIB) announced the decision to terminate development of BIIB105 (ION541) an investigational antisense oligonucleotide (ASO) for amyotrophic lateral sclerosis (ALS) based on topline results from the Phase 1/2 ALSpire study.

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the Company’s senior management team will participate in the following investor conferences in May and June 2024.

Soligenix, Inc. announced today that the results of its compatibility study evaluating HyBryte™ (synthetic hypericin) for the treatment of cutaneous T-cell lymphoma (CTCL) have been published in the Journal of the European Academy of Dermatology & Venereology (JEADV) Clinical Practice.

Agenus Inc. today announced it will conduct a Type B End-of-Phase 2 (EOP2) meeting in July with the U.S. Food and Drug Administration (FDA) to discuss the botensilimab plus balstilimab (BOT/BAL).

CNS Pharmaceuticals, Inc. today reported its financial results for the first quarter 2024 ended March 31, 2024.

EDAP TMS SA, the global leader in robotic energy-based therapies, reported unaudited financial results for the first quarter of 2024.

MoonLake Immunotherapeutics today announced that the first patients have been screened at a U.S. trial site in its global Phase 3 clinical program, VELA, evaluating sonelokimab, an investigational Nanobody® designed to treat inflammatory disease, in patients with moderate-to-severe hidradenitis suppurativa (HS).

NKGen Biotech, Inc. announced that Paul Y. Song, MD, Chairman and Chief Executive Officer of NKGen, will present highlights of the Company’s cryopreserved, autologous, non-genetically modified NK cell therapy product, SNK01 at the 5th International Cell & Gene Therapy China Summit & Exhibition to be held in Nanjing, China, from May 22–24, 2024.

Ventyx Biosciences, Inc. today announced the appointment of industry veteran Matthew Moore as Chief Operating Officer.

Kane Biotech Inc. will release its first quarter 2024 financial results after market close on Thursday, May 23, 2024.